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The Royal Marsden Hospital and the Institute for Cancer Research, Surrey, UK Summary:
A total of 81 adults with acute myeloid leukemia (AML) (47% favorable karyotypes) were autografted in first remission after melphalan-total body irradiation, having received 0 (n ¼ 7), 1 (n ¼ 19), 2 (n ¼ 51), or 3 (n ¼ 4) consolidation chemotherapy cycles before harvest. The cumulative 5-year incidences of relapse and transplantrelated mortality were 37 and 17%, respectively. The actuarial 5-year probability of disease-free survival (DFS) was 46%. In Cox analysis, favorable karyotypes, increasing numbers of consolidation cycles (0 vs X1 or 1 vs 41), and higher nucleated cell doses were associated with lower relapse rates and higher DFS. Patients with favorable karyotypes benefited from every additional cycle of consolidation therapy (0 vs X1 as well as 1 vs 41). Among patients with other karyotypes, while the benefit of one cycle of consolidation was clear (0 vs X1), there was no obvious beneficial impact of further consolidation therapy (1 vs 41). Administration of consolidation chemotherapy prior to harvest is essential in AML. While it is possible to enhance the benefit of consolidation with favorable karyotypes by delivering two cycles, its usefulness is limited in others. In them, it may be worthwhile exploring alternatives not normally used in AML (eg high-dose cyclophosphamide) that could have antileukemic effects while permitting mobilization of stem cells Bone Marrow Transplantation (2003) 32, 157-164. doi:10.1038/sj.bmt.1704119 Keywords: acute myeloid leukemia; autotransplantation; consolidation chemotherapy; cytogenetics; karyotype A number of biological factors affect the outcome of autotransplantation in acute myeloid leukemia (AML). The foremost among these is the karyotype.
1,2 Treatmentrelated factors such as the amount of consolidation chemotherapy administered before the collection of autologous cells -akin to an in vivo purging effect -can also affect outcome. 3 The clinical utility of identifying a treatment-related prognostic factor is the possibility of manipulating or modifying it in practice to improve results.
Based on our previous findings, 3 we have suggested that marrow-or blood-derived stem cells for autotransplantation in AML should be collected after completion of two cycles of consolidation chemotherapy. When we suggested this, we assumed that this was applicable to all patients because we did not have enough data to analyze the effect of specific cytogenetic subtypes.
Is there reason to believe that the effect of treatment intensity is modulated by the karyotype? The beneficial impact of high-dose cytarabine-based consolidation chemotherapy in AML 4 is much greater in patients with favorable karyotypes (t(8;21), inv(16) and t(16;16)) than in those with normal karyotypes. 5 Patients with other karyotypes did not benefit from high-dose cytarabine at all in that study. 5 Among patients with the t(8;21) abnormality, the administration of at least three cycles of high-dose cytarabine was associated with superior outcome compared with those receiving only one cycle. 6 The current analysis was undertaken to characterize the relation between pretransplant chemotherapy and karyotype in determining the prognosis of patients with AML autografted in first complete remission (CR) after a uniform conditioning regimen.
Patients and methods
Prospectively gathered data 7 on 81 consecutive AML patients over the age of 15 years with known karyotypes who were autografted after melphalan and total-body irradiation (TBI) for AML in first CR (morphologic as well as cytogenetic) between February 1987 and January 2001 at the Leukaemia Unit of the Royal Marsden Hospital were analyzed. These patients did not have HLA-identical sibling donors. Patients with biphenotypic disease and those with a history of antecedent hematologic neoplasia or cytotoxic chemotherapy were excluded. Of these patients, 41 were included in our previous report on autotransplan-tation for AML, 3 in which the effect of karyotype was not analyzed. 1 Thus, while the nonfavorable karyotype group has been referred to as 'other' throughout the study, it essentially reflects patients with intermediate karyotypes.
Of the 16 patients with t(15;17), 10 were autografted in 1993 or earlier, and had not received retinoic acid therapy. First remission transplantation was essentially abandoned after 1993 for t(15;17) patients. Six autografts were performed after retinoic acid became available in the United Kingdom because of lack of retinoic acid therapy (n ¼ 3; treated in other countries), high leukocyte count at presentation (n ¼ 1), and physician preference (n ¼ 2).
All research protocols were approved by the institutional review board of the Royal Marsden Hospital. All patients gave informed consent for the transplant.
Induction and consolidation chemotherapy
Patients had either been treated elsewhere and referred to the Royal Marsden Hospital in first CR for autotransplantation (n ¼ 25) or had presented untreated to the Royal Marsden Hospital with newly diagnosed disease (n ¼ 56). The former had received standard two-or three-drug induction chemotherapy containing an anthracycline and conventional-dose cytarabine, with or without etoposide or 6-thioguanine in accordance with the MRC AML 10 study. 8 The latter received high-dose cytarabine and etoposide with (n ¼ 39) or without (n ¼ 17) idarubicin. 9 Patients receiving conventional induction therapy usually received the same chemotherapy combination, amsacrinecytarabine-etoposide (MACE) or mitoxantrone-intermediate-dose cytarabine (MiDAC) as consolidation. 8 Only 6 of these patients received high-dose cytarabine as consolidation therapy. None of the patients receiving high-dose cytarabine-based induction received high-dose cytarabine consolidation. Consolidation among these patients usually comprised 6-thioguanine-cytarabine and MACE. Bone marrow and blood stem cell harvest
Bone marrow was harvested from the posterior iliac crests under general anesthesia, usually 4-6 weeks after completion of final consolidation therapy when blood counts had recovered. In the minority of patients receiving bloodderived stem cells, 12-16 mg/kg filgrastim was used for mobilization on days 1-4, and stem cells were harvested on days 4 and 5. Leukapheresis was performed on a Cobe Spectra (Cobe Industries, Lakewood, CO, USA) continuous-flow cell separator with 150-200% of the patient's calculated blood volume being processed at each session.
No chemotherapy was administered after collection of cells.
Cryopreservation and infusion
Patients receiving fresh marrow (1986-1990) were harvested on day À1 in the morning under general anesthesia, and the marrow was stored in the refrigerator for 24 h prior to infusion on day 0. From 1991 onwards, all patients received cryopreserved cells. Cells were cryopreserved with 10% dimethylsulfoxide using a programmed rate freezer, and were stored in the vapor phase of liquid nitrogen. The cells were rapidly thawed in a water bath at 371C by the bedside and infused on day 0, usually within 2 weeks of the collection.
High-dose therapy and transplant
The conditioning regimen for ABMT was 110 (1986) (1987) (1988) or 140 mg/m 2 (1989 onwards) melphalan on day À1 and 1050 cGy TBI on day 0 TBI was delivered from opposed 60 Co sources at a low dose rate (4 cGy/min) in a single fraction. Autologous marrow or blood stem cells were infused on day 0. No growth factors were administered post-transplant.
Supportive care
All patients were treated in protective isolation in rooms with positive-pressure ventilation. Blood products transfused were not screened for cytomegalovirus (CMV) antibody in CMV-seropositive patients. Antibiotic prophylaxis and therapy varied in accordance with prevalent practices and research programs. Broad-spectrum antibiotic therapy was started for fever in the neutropenic phase. Irradiated random platelets were transfused to maintain the platelet count at 20 Â 10 9 /l, and packed cells to maintain the hemoglobin at 100 g/l.
Statistical analysis
All follow-up data are current as of 31 March 2002. The w 2 test was used to compare categoric variables and the Wilcoxon rank-sum test was used to compare continuous variables. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by the KaplanMeier method, and compared using the log-rank test. Cumulative incidence of transplant-related mortality (TRM) and relapse was estimated using each type of event as a competing risk for the other. The significance of differences in TRM and relapse was calculated using the likelihood-ratio statistic for proportional-hazards regression models.
Two patients dying in CR of causes obviously unrelated to the transplant and the underlying disease (intracerebral hemorrhage probably related to a vascular malformation and community-acquired methicillin-resistant Staphylococcus aureus pneumonia at 5.4 and 13.2 years respectively) were censored at the time of death for OS and DFS, and were considered competing events for calculating the cumulative incidence of TRM and relapse.
The following factors were analyzed in univariate fashion for effect on TRM, relapse, DFS, and OS: gender, age (o35 vs X35 years), cytogenetics (favorable vs other), number of cycles of induction chemotherapy to attain CR (1 vs 41), type of induction therapy (high-vs conventionaldose cytarabine-based), number of cycles of consolidation chemotherapy (0 vs X1, 1 vs 41; analyzed separately), exposure to high-dose cytarabine (yes vs no), CR-transplant interval (o90 vs X90 days), source of stem cells (marrow vs blood), total nucleated cell dose (42 vs p2 Â 10 8 /kg), cryopreservation (yes vs no), and melphalan dose (110 vs 140 mg/m 2 ). In order to judge the impact of a single cycle of consolidation chemotherapy more accurately, the seven patients receiving no consolidation therapy at all (who had a dismal outcome; vide infra) were excluded when comparing one cycle to more than one cycle. Table 2 Relation between the amount of consolidation chemotherapy and the other four variables found to affect outcome significantly in univariate analysis Number of cycles of consolidation chemotherapy P Of the five factors found to be significant in univariate analysis, three were entered into a Cox proportionalhazards model to check for independent effect on relapse, TRM, DFS, and OS. These were cytogenetics, the number of cycles of consolidation chemotherapy (0 vs X1, 1 vs 41; analyzed separately), and total nucleated cell dose (42 vs p2 Â 10 8 /kg). The two variables found to be significant in univariate analysis that were not entered in the Cox model were the number of cycles to attain CR and the CR-transplant interval because of a close correlation between these parameters and the intensity of consolidation chemotherapy (Table 2 ). There were no other significant interactions between the other variables entered in the Cox model and the amount of consolidation chemotherapy administered (Table 2) . The amount of consolidation chemotherapy used as a covariate differs in the two models (no consolidation vs any consolidation, and one cycle of consolidation vs two to three cycles of consolidation.
Results
Neutrophil and platelet recovery were slow as is characteristic of patients with AML, and were significantly slower for those receiving lower TNC doses (details not shown).
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Transplant-related morbidity and mortality A total of 13 patients died of causes related to the transplant at 15-1603 days (median 220) post-transplant, most of infectious or hemorrhagic consequences of low counts. The cumulative incidence of treatment-related mortality at 10 years was 17% (95% CI: 10-29%). None of the eight patients receiving blood-derived stem cells died compared with 13 of 73 receiving marrow (P ¼ 0.23). The 10-year cumulative incidence of TRM for patients receiving 42 Â 10 8 nucleated cells/kg was 15% (95% CI: 8-27%) compared with 33% (95% CI: 15-74%) for those receiving p2 Â 10 8 nucleated cells/kg (P ¼ 0.02).
Relapse
A total of 29 patients relapsed at 2-43 months (median 9). All relapsed patients died; as a consequence of relapsed disease or toxicity of salvage therapy. The cumulative incidence of relapse at 10 years was 37% (95% CI: 27-49%; Figure 1 ). The 10-year cumulative incidence of relapse for patients with favorable karyotypes was 24% (95% CI: 14-42%) compared with 48% (95% CI: 35-66%) for those with other karyotypes (P ¼ 0.02).
Disease-free survival
As of the last follow-up, 39 patients were alive and well in continuous first CR 1.2-15.2 years (median 5.3) post transplant. The actuarial 10-year probability of DFS ( Figure 2 ) was 46% (95% CI: 35-57%). The actuarial 10-year DFS for patients with favorable karyotypes was 60% (95% CI: 44-76%) compared with 34% (95% CI: 18-49%) for those with other karyotypes (P ¼ 0.02). The actuarial 10-year DFS of patients receiving 42 Â 10 8 nucleated cells/kg was 51% (95% CI: 39-64%) compared with 17% (95% CI: 0-38%) for those receiving p2 Â 10 8 nucleated cells/kg (P ¼ 0.002).
Cox analysis
As Table 3 shows, a higher nucleated cell dose, a greater number of cycles of consolidation chemotherapy, and favorable cytogenetics were independent good-risk factors for outcome. 
Effect of consolidation chemotherapy by risk group
The beneficial effect of the amount of consolidation chemotherapy administered differed by the cytogenetic subgroup (Table 4) . While getting some consolidation chemotherapy was important for all patients (0 vs 1-3 cycles), increasing extent of therapy (1 vs 2-3 cycles) among those receiving consolidation appeared to benefit only patients with favorable karyotypes (Figures 3 and 4) , with no obvious benefit to patients with other karyotypes (Figures 5 and 6 ).
Discussion
In this study, we confirm our previous observation that the intensity of pretransplant therapy-measured simply as the number of cycles of consolidation chemotherapy delivered before the collection of autologous cells and transplantation-has a significant impact on the outcome of autografted AML patients. 3 In the previous study, 3 the impact of cytogenetics could not be analyzed because karyotypes were available in only 41 of 74 patients. The present analysis has been confined to patients with known karyotypes to assess the impact of prior therapy in the context of disease biology. Also, in the previous study, 3 the amount of consolidation chemotherapy was considered 'inadequate' (none or only one cycle) or 'adequate' (more than one cycle; usually two). In the current study, the need for consolidation chemotherapy has been assessed by analyzing the outcome of no consolidation vs any consolidation, and the impact of increasing intensity by analyzing the outcome of those receiving one course vs those receiving more than 1 course. Patients receiving no consolidation at all, who had a dismal outcome, were excluded from the latter comparison in order to avoid any bias that could result in the outcome of the low-intensity group seeming worse than it really was.
The shortcoming of this study is that some of the subgroups of patients were very small, especially those autografted with no prior consolidation therapy at all. However, because the outcome of these smaller groups is so strikingly different from the other patients, we feel that the data are suggestive enough to support our conclusions. The strength of the study is that the patients have been treated uniformly at a single institution and minute details of therapy are available. 7 Data from one of the cooperative transplant registries are not detailed enough to enable this sort of an analysis. In fact, for a recent case-control comparison of some of the marrow autograft recipients from the Royal Marsden Hospital with blood autograft recipients from the European Blood and Marrow Transplantation (EBMT) group, 11 because of lack of consolidation chemotherapy data on the EBMT patients, we had to use the CR-transplant interval (one of the criteria for selecting control patients) as a surrogate marker for the amount of consolidation chemotherapy received by the EBMT patients.
Our data show that giving some consolidation chemotherapy is essential because patients autografted with no prior consolidation chemotherapy all died, mostly of relapse. It should be clarified that these patients were all autografted very early on when little was known about autotransplantation in AML and nothing about the impact of prior therapy on outcome. This was true for patients with good karyotypes as well as other patients (Table 4) .
The more interesting observation is that among patients who did receive consolidation therapy, delivering at least two cycles improved the outcome of patients with favorable karyotypes dramatically compared to those receiving only one cycle of consolidation. On the other hand, delivering 41 cycle of consolidation did not seem to confer any additional benefit to patients with other karyotypes over that achieved with a single cycle of consolidation. This observation appears to be in keeping with that made in AML patients receiving repeated cycle of high-dose cytarabine as consolidation where only patients with favorable karyotypes benefited from treatment intensification. 5 If patients with favorable karyotypes [t(8;21) and inv (16) ] are subjected to autotransplantation in first CR, our data suggest that they should receive at least two Impact of cytogenetics on outcome in AML J Mehta et al cycles of consolidation prior to collection of stem cells for optimization of outcome. Although our data did not show any obvious beneficial effect of high-dose cytarabine either during induction or during consolidation, based upon the beneficial effect of high-dose cytarabine seen in conventional treatment of AML, [4] [5] [6] at least one of the cycles should probably comprise high-dose cytarabine.
We do not believe that these data are conclusive enough to justify omission of the second course of consolidation chemotherapy in patients with karyotypes that are other than favorable. It is conceivable, for example, that these patients require additional consolidation chemotherapy (a third course) prior to collection of cells for optimizing outcome. The other possibility is that since the second cycle of standard AML-type consolidation chemotherapy is not beneficial, it should be a very different type of therapysuch as high-dose cyclophosphamide with or without etoposide -that could also be a good stem cell-mobilizing regimen. Until data are available to support one of these two potential alternative approaches to improve outcome of autotransplantation in patients with nonfavorable karyotypes, a compromise solution may be to deliver three courses of consolidation chemotherapy, with a third course based on high-dose cyclophosphamide for peripheral blood stem cell mobilization and collection. The first and the second courses of consolidation chemotherapy would be standard AML-type combinations, and could, based upon our data as well as those from CALGB, 5 exclude high-dose cytarabine from at least one. While it is important to emphasize the speculative nature of these suggestions because there are no data to substantiate them, it is also worth remembering that there are no ongoing prospective studies that will resolve these issues.
This study cannot help resolve the contentious issue of autotransplantation for AML in first CR. 2, [12] [13] [14] Our data however may explain, in part, why some studies have not found autotransplantation to be beneficial. The studies that found no benefit 12-14 for autotransplantation had specified only a single course of consolidation chemotherapy prior to collection of cells and transplantation, which may not be the optimal technique. The MRC AML 10 study, which did show a significant reduction of relapse and improved disease-free survival with autograft, 2 specified collection of cells after the third course of chemotherapy, which would have been the second consolidation course in most patients (attaining CR with a single cycle of induction) and the first consolidation course in some (those attaining CR after the second cycle of induction chemotherapy).
One of the problems with autotransplantation, especially when compared to chemotherapy, has been treatmentrelated mortality. This is another factor which has contributed to lack of a survival advantage among autografted patients when compared with intensive chemotherapy. Our data show that ensuring the delivery of an adequate nucleated cell dose is likely to alleviate this problem to a substantial extent. An easy way to do this is to use blood-derived stem cells instead of marrow-derived cells. 10 A case-control comparison of marrow recipients from our group of patients with blood recipients from EBMT showed a significant reduction in treatment-related mortality (seven of 57 marrow recipients compared with one of 114 blood recipients; P ¼ 0.04).
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The overall outcome of patients with favorable karyotypes treated on the MRC AML 10 study is excellent when all three treatment arms (allograft, autograft, and no transplant) are analyzed together. 15 These data are often interpreted to support the position that autotransplantation is not necessary for patients with favorable karyotypes in first CR. However, in the MRC AML 10 study, the outcome of the good karyotype subgroup subjected to autotransplantation is superior to the no-transplant group in terms of significantly lower relapse, significantly higher DFS, and nonsignificantly superior OS. 2 Since our data also suggest a role of increasing treatment intensification in improving the outcome of patients with favorable karyotypes, it could be argued that this is the group [t(8;21) and inv (16) ; not t(15;17)] in which autotransplantation should be performed in first CR if there is no HLA-matched sibling donor. If there is an HLA-matched sibling donor, an allograft can be deferred until relapse. Despite limited data, it is noteworthy that the long-term DFS of the 23 patients with favorable karyotypes who were optimally treated (good cell dose and two cycles of consolidation therapy) is 87% (95% CI: 72-100%). 16 This observation, in our opinion, should prompt consideration of autotransplantation in patients with favorable karyotypes in first CR.
In conclusion, our data show that it is important to treat AML adequately initially because this affects the outcome of autotransplantation. The extent of therapy required for optimizing outcome varies by karyotype, and appears to be greater for patients with favorable karyotypes.
